Asset
Venetoclax
Prelude Therapeutics Incorporated Common Stock
Revenue
No revenue reported in loaded filings.
Clinical trials (2)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT05665530 | phase1 | completed | 2023-09-12 | 2025-06-12 | Prelude Therapeutics | A Study of PRT2527 as Monotherapy and in Combination With Zanubrutinib or Venetoclax in Participants With R/R Hematologic Malignancies |
| NCT05107856 | phase1 | terminated | 2022-03-22 | 2024-01-19 | Prelude Therapeutics | PRT1419 as Monotherapy or in Combination With Azacitidine or Venetoclax in R/R Myeloid or B-cell Malignancies |
FDA applications (0)
This company has no applications containing this asset.